

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Tong Ren Tang Technologies Co. Ltd.
北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

VOLUNTARY ANNOUNCEMENT

This announcement is made by the board of directors (the “**Board**”) of Tong Ren Tang Technologies Co. Ltd. (the “**Company**”) on a voluntary basis.

To the best knowledge of the directors, the workshops and production lines of pharmaceutical factory of the Company have complied with the requirements of the Good Manufacturing Practice (“**GMP**”) upon on-site inspection and technical audit and received the GMP Certificate issued by Beijing Food and Drug Administration. The related information is hereby announced as follows:

I. Information related to GMP certificate

Certificate Number: BJ20170302

Name of Enterprise: Pharmaceutical Factory of Tong Ren Tang Technologies Co. Ltd.

Address: No. 20, Nansanhuan Zhong Road, Fengtai District, Beijing. West Xiaogudian Village, Qingyundian Town, Daxing District, Beijing. Six buildings including No. 201 of East Dongyonghetun Village, Tongzhou District, Beijing (Shared workshop within the Group). Three groups of Changhe Village, Xinglong Town, Longquanyi District, Chengdu, Sichuan Province (Shared workshop within the Group).

Scope of Authentication: Mixture (including oral liquid), Syrup, Electuary (ointment), Liniment (liniment), Tincture (including external), Spray, Dropping pills. Preprocessing of traditional Chinese medicine. Extraction of traditional Chinese medicine. Preprocessing of traditional Chinese medicine and extraction of traditional Chinese medicine.

Date of Issue: 11 December 2017

Expiry Date: 10 December 2022

II. The status of production line related to GMP certificate

No.	Name of production line	Designed production capacity	Key product(s)
1	Production line for extraction of traditional Chinese medicines	Tongzhou Dongyonghetun: 1 million kg Chengdu: 1 million kg	As the production line is for the preprocessing process of the production, there is no key product.
2	Production line for preprocessing traditional Chinese medicines	Processing quantity of net material-Daxing Qingyundian: 15 million kg Crushing quantity of raw material- Daxing Qingyundian: 10 million kg	As the production line is for the preprocessing process of the production, there is no key product.
3	Production line of liquid preparation workshops	Mixture (including oral liquid): 25 million pieces Syrup: 4 million boxes Electuary (ointment): 4 million boxes Liniment (liniment): 0.4 million boxes Tincture (including external): 35 million pieces Spray: 0.4 million boxes Dropping pills: 2.4 million boxes	Shengmaiyin (生脈飲), Huoxiang Zhengqi Liquid (藿香正氣水), Fufang Yimucao Paste (複方益母草膏), etc.

III. Market condition of key product(s)

No.	Product Name	Dosage Form	Functions and Indication	Major Production Enterprises	Information of Similar Products in the Market
1	Shengmaiyin (生脈飲)	Mixture (oral liquid)	Tonifying qi and yin, and promoting the secretion of saliva or body fluid. Applicable to deficiency of both qi and yin, palpitations and shortness of breath, and spontaneous perspiration.	Pharmaceutical factory of the Company, Zhongjing Wanxi Pharmaceutical Co., Ltd. (仲景宛西製藥股份有限公司), Guilin Sanjin Pharmaceutical Company Limited (桂林三金藥業股份有限公司) etc.	A total of 179 enterprises were granted the approval number for such product. The sales revenue of the product of the Company in 2016 was about RMB56,120,000.
2	Huoxiang Zhengqi Liquid (藿香正氣水)	Tincture	Relieving exterior syndrome, eliminating dampness, and regulating qi and the middle warmer. Applicable to cold caused by exogenous cold and endogenous damp stagnation or summer-heat dampness, including symptoms of headache and confusion, stuffy sensation in the chest and diaphragm, gastric distension and pain, vomiting and diarrhea. Gastrointestinal cold belongs to the above-mentioned symptoms.	Pharmaceutical factory of the Company, Yunnan Baiyao Co., Ltd. (雲南白藥集團股份有限公司), Zhongjing Wanxi Pharmaceutical Co., Ltd. (仲景宛西製藥股份有限公司) etc.	A total of 173 enterprises were granted the approval number for such product. The sales revenue of the product of the Company in 2016 was about RMB14,510,000.

3	Fufang Yimucao Paste (複方益母草膏)	Electuary	Regulating menstruation and nourishing the blood, dispersing blood stasis and generating new blood. Applicable to irregular menstruation caused by blood stasis and stagnancy of qi, menstrual abdominal pain, and hypomenorrhea and dark color.	Pharmaceutical factory of the Company, Beijing Dongsheng Pharmaceutical Co., Ltd. (北京東升製藥有限公司), Tianjin Beauty Medicine Group Co., Ltd. (天津美倫醫藥集團有限公司) etc.	A total of 5 enterprises were granted the approval number for such product. The sales revenue of the product of the Company in 2016 was about RMB6,680,000.
---	-------------------------------	-----------	--	---	---

Note:

1. The above information is sourced from the official website of China Food and Drug Administration, etc.;
2. The Company could not obtain the specific sales information on the same type of products in the market through public information;
3. The above statistical results may be not comprehensive enough, and are for the purpose of reference only.

IV. Impact on the Company

This is a re-authentication after the expiration of the original GMP Certificate. The aforesaid workshops passed the GMP authentication and were granted GMP Certificate, which indicates that the related production lines of the Company meet the requirements of new version of GMP. The obtaining of the GMP Certificate for this time will be beneficial to maintain the stable production capacity of the Company and meet the market demands, and meanwhile it will not have any significant impact on the production and operation of the Company.

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Gao Zhen Kun
Chairman of the Board

Beijing, the PRC
20 December 2017

As at the date of this announcement, the Board comprises Mr. Gao Zhen Kun, Mr. Gu Hai Ou, Mr. Rao Zu Hai, Mr. Li Bin, Mr. Wang Yu Wei and Ms. Fang Jia Zhi as executive Directors; Miss Tam Wai Chu, Maria, Mr. Ting Leung Huel, Stephen and Mr. Jin Shi Yuan as independent non-executive Directors.